

30 January 2025

## ON-MARKET SHARE BUY-BACK

Mach7 Technologies Limited ("M7T" or "the Company") (ASX: M7T) today announces the implementation of an on-market share buy-back program with a maximum value of up to A\$5M. The expected commencement date is 3 March 2025 for a period of up to 12 months ("buy-back").

The Board considers the buy-back to be an efficient use of capital given the strength of Mach7's balance sheet and strong cash inflows to date (A\$25.3M cash balance as at 29 January 2025). It is part of the Company's ongoing capital management strategy and highlights the Board's confidence in Mach7's future growth prospects.

Mach7 CEO and Managing Director Mike Lampron said: "We have grown our brand significantly to now compete with some of the largest players in the medical imaging informatics sector. Our consistent cash growth over the past three years and ongoing positive trend in our cash position gives us confidence in the strength and continued success of our business."

"In the initial phase of our capital management strategy, we reinvested in the business to drive growth and innovation while maintaining our strong customer base. As we move into the next phase, we believe that a share buy-back is an effective capital management initiative given our solid financial position and confidence in the Company's future performance. It also demonstrates our belief that the current share price significantly undervalues Mach7."

Mach7 reaffirms its FY25 guidance for CARR and revenue growth of 15-25% and for opex growth to be less than revenue growth.

In accordance with ASX Listing Rules, the price paid for the shares purchased under the buy-back will be no more than 5% above the volume weighted average price of Mach7 shares over the five trading days prior to purchase.

The number of shares purchased under the buy-back will depend on several factors including business and market conditions, the prevailing share price, available investment opportunities and other relevant considerations. The number of Mach7 shares acquired will not exceed the "10/12" limit prescribed in the Corporations Act and will not require shareholder approval. The Company reserves the right to suspend without notice or terminate the buy-back program at any time.

The number of shares purchased under the buy-back and the average price will be notified to the ASX on the business day following the date on which those shares are bought back. Shares bought back will be cancelled upon acquisition and the number of shares on issue will reduce accordingly.

The Company advises all shareholders that there can be no certainty that it will acquire any or all shares under the share buy-back.

The buy-back will be managed by Morgans Financial Limited on behalf of the Company.

**Released on authority of the Board by:**

Mike Lampron  
Managing Director and Chief Executive Officer

**For more information, contact:**

**Investor Relations**

Françoise Dixon  
+61 (0) 412 292 977  
[ir@mach7t.com](mailto:ir@mach7t.com)

**About Mach7 Technologies:**

Mach7 Technologies (ASX:M7T) is a medical imaging technology provider that develops innovative data management and image viewing solutions for healthcare organizations. Its core offering is the Mach7 Enterprise Imaging Solution (EIS), a next-generation platform built for the future of healthcare, comprised of a Vendor Neutral Archive (VNA), eUnity Enterprise Diagnostic Viewer, and Diagnostic Workflow Applications. Designed to maximize flexibility and scalability, Mach7 gives customers the independence to deploy a full enterprise solution or individual components. Mach7 serves a global network of customers, ranging from expansive IDNs and National Health Systems to small, independent provider groups and private radiology practices. Visit [Mach7t.com](http://Mach7t.com) for more information.

**Forward-looking statements**

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.

